Source: Annual Congress 2011 - Novel mechanisms in COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Adler, M. Kraft, I. Parikh, E. Murphy, A. Van As (Raleigh, Durham, Philadelphia, United States Of America). Results of a phase 2a clinical trial with a peptide inhibitor of MARCKS protein indicate improvement of indices of bronchitis and lung function in patients with COPD. Eur Respir J 2011; 38: Suppl. 55, 4901

Member's Comments

No comment yet.

Related content which might interest you: Use of a prostasin antagonist, AER 002, in obstructive lung disease: results of two phase 2 clinical trials in CF and COPD Source: Annual Congress 2008 - Cystic fibrosis: novel aspects of airway function and inflammation Year: 2008 Cilomilast, a potent, selective inhibitor of phosphodiesterase 4, improves small airway function in patients with chronic obstructive pulmonary disease: results of a 6-month trial Source: Eur Respir J 2001; 18: Suppl. 33, 94s Year: 2001 Preliminary results of relationship between appetite and clinical presentation of COPD patients in AERIS study Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015 Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Mometasone/indacaterol/glycopyrronium (MF/IND/GLY) improves lung function and reduces exacerbations in patients with asthma, independent of baseline airflow limitation: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 COPD exacerbations in the phase 3 revefenacin clinical trial program Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018 The magnitude of pirfenidone treatment effect in patients with idiopathic pulmonary fibrosis (IPF): A pooled analysis of outcomes in the CAPACITY (CAP) studies Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Regional differences in the treatment of patients with moderate COPD enrolled in a global clinical trial Source: Annual Congress 2006 - Recent advances in the treatment of COPD Year: 2006 Effect of roflumilast on lung function: Results from 180-days study in subjects With severe COPD Source: Annual Congress 2013 –COPD mechanisms Year: 2013 Extended analysis of phase III trial of pirfenidone: More pronounced effect in mild impairment of patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 The effect of an acute exacerbation of COPD (AECOPD) on balance after pulmonary rehabilitation (PR): a prospective study Source: International Congress 2017 – Assessing the functional status of patients with COPD Year: 2017 Revefenacin (REV) improves health status and dyspnea regardless of baseline symptom status in chronic obstructive pulmonary disease (COPD): a post hoc analysis of phase 3 trials Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils Year: 2020 Is physical activity a determinant for change in FEV1 in COPD patients? A prospective cohort study Source: International Congress 2015 – Best abstracts in physical activity in chronic lung diseases Year: 2015 LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 COPD in the time of COVID-19: an analysis of acute exacerbations and reported behavioural changes in patients with COPD Source: ERJ Open Res, 7 (1) 00718-2020; 10.1183/23120541.00718-2020 Year: 2021 Outcomes for COPD pharmacological trials: from lung function to biomarkers Source: Eur Respir J 2008; 31: 416-469 Year: 2008 Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014 Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015 Effect of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on baseline blood eosinophil counts: Results from the FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Effect of low dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real life study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021